<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172274</url>
  </required_header>
  <id_info>
    <org_study_id>1245.8</org_study_id>
    <nct_id>NCT02172274</nct_id>
  </id_info>
  <brief_title>BI 10773 Administered as Oral Solution to Healthy Male Volunteers</brief_title>
  <official_title>A Phase I, Open-label, Single-dose Trial to Investigate the Metabolism and Pharmacokinetics of 50 mg [14C]-BI 10773 When Administered as Oral Solution to Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the pharmacokinetics of BI 10773 and total radioactivity including
      excretion mass balance, excretion pathways and metabolism following the oral administration
      of [14C] BI 10773
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum concentration of the analyte in plasma)</measure>
    <time_frame>pre-dose and up to 144 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte in plasma)</measure>
    <time_frame>pre-dose and up to 144 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>pre-dose and up to 144 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to infinity)</measure>
    <time_frame>pre-dose and up to 144 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>pre-dose and up to 144 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (terminal half-life of the analyte(s) in plasma)</measure>
    <time_frame>pre-dose and up to 144 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRTpo (mean residence time of the analyte(s) in the body after oral administration)</measure>
    <time_frame>pre-dose and up to 144 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F (apparent/total clearance of the analyte(s) in plasma after an extravascular dose)</measure>
    <time_frame>pre-dose and up to 144 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz after an extravascular dose)</measure>
    <time_frame>pre-dose and up to 144 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>feurine,0-tz (amount of analyte excreted in urine over the time interval from 0 to the time of the last quantifiable data point in % of dose, additionally excretion within each sampling interval will be calculated)</measure>
    <time_frame>pre-dose and up to 168 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fefaeces,0-tz (amount of analyte excreted in faeces over the time interval from 0 to the time of the last quantifiable data point in % of dose, additionally excretion within each sampling interval will be calculated)</measure>
    <time_frame>pre-dose and up to 168 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR,0-tz (renal clearance of analyte)</measure>
    <time_frame>pre-dose and up to 168 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual concentration-time profiles of [14C] radioactivity in whole blood, plasma, urine, and faeces</measure>
    <time_frame>up to 8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual concentration-time profiles of BI 10773 in plasma and urine</measure>
    <time_frame>up to 8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces</measure>
    <time_frame>up to 8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of major metabolites in urine, faeces, and plasma</measure>
    <time_frame>up to 8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cblood cell/Cplasma ratio of [14C]-radioactivity</measure>
    <time_frame>up to 8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the plasma protein binding of total [14C] radioactivity in human plasma samples ex vivo</measure>
    <time_frame>up to 8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal findings in physical examination</measure>
    <time_frame>Baseline and within 6 days after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)</measure>
    <time_frame>Baseline, days 1, 2, 7 and within 6 days after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal findings in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Baseline, days 1, 2, 7 and within 6 days after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>Baseline, days 1, 2 and within 6 days after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[14C]-BI 10773 - oral solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-BI 10773 - oral solution</intervention_name>
    <arm_group_label>[14C]-BI 10773 - oral solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males according to a complete medical history, including a physical
             examination, vital signs (blood pressure, pulse rate), 12-lead ECG
             (electrocardiogram), and clinical laboratory tests

          -  Age 18 to 55 years, inclusive

          -  Body mass index 18.5 to 29.9 kg/m2, inclusive

          -  Nonsmoker

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with GCP (Good Clinical Practice) and the local legislation

        Exclusion Criteria:

          -  Any finding in the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, hormonal, psychiatric or neurological disorders (including all forms of
             epilepsy)

          -  Surgery of the gastrointestinal tract (except appendectomy)

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Subjects with Gilbert's Syndrome

          -  Chronic or relevant acute infections

          -  History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          -  Intake of drugs with a long half-life (&gt;24 hours) within one month prior to
             administration of the trial drug

          -  Use of prescription medication, over-the-counter drugs or herbal preparations within
             14 days prior to administration of the trial drug

          -  Participation in another trial with an investigational drug within two months prior to
             administration of the trial drug or during the trial

          -  History or evidence of habitual tobacco or nicotine use within six months prior to
             administration of the trial drug

          -  Alcohol abuse (more than 60 g/day)

          -  Drug abuse in opinion of investigator

          -  Blood donation (more than 100 mL within four weeks prior to administration of trial
             drug or during the trial)

          -  Excessive physical activity within five days prior to administration of trial drug

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of trial centre

          -  A marked baseline prolongation of QT/QTc interval (corrected QT interval)(e.g.,
             repeated demonstration of a QTc interval &gt;450 ms)

          -  Male subjects must agree to minimise the risk of female partners becoming pregnant
             from the dosing day until three months after the completion of the study. Acceptable
             methods of contraception for male volunteers include a vasectomy no less than three
             months prior to dosing, barrier contraception, or a medically accepted contraceptive
             method. For female partners of male volunteers, acceptable methods of contraception
             include intrauterine device, tubal ligation, hormonal contraceptive for at least two
             months, or diaphragm with spermicide

          -  Participation in more than one other radiolabeled investigational drug trial within
             one year prior to administration of the trial drug. The previous radiolabeled trial
             drug must have been received more than six months prior to administration of the trial
             drug for this study, and the total exposure from this study and the previous study
             will be within the recommended levels considered safe, per 21 CFR (Code of Federal
             Regulations) 361.1 (eg, less than 5000 mrem whole body annual exposure)

          -  Irregular defecation pattern (less than one bowel movement a day)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

